Centro Hospitalar e Universitário de Coimbra, EPE, 3004-561, Coimbra, Portugal.
QLV Research Consulting, 3030-199, Coimbra, Portugal.
Clin Transl Oncol. 2024 Oct;26(10):2431-2443. doi: 10.1007/s12094-024-03491-8. Epub 2024 Apr 24.
Treatment of cancer has been improved with the discovery of biological drugs that act as immune checkpoint inhibitors. In 2017, FDA designated pembrolizumab, an immune checkpoint inhibitor employed in immunotherapy, as the first tissue-agnostic cancer treatment.
To review pembrolizumab's use in oncology, gather and examine the latest discoveries regarding the effectiveness of pembrolizumab in cancer treatment.
A literature review was conducted through PubMed(Medline) from January 2015 to December 2023 using "pembrolizumab", "cancer" and "treatment" as search terms.
Pembrolizumab demonstrated effectiveness as primary treatment for metastatic nonsmall cell lung cancer, unresectable esophageal cancer, head and neck squamous cell carcinoma and alternative treatment for notable triple-negative breast cancer, biliary, colorectal, endometrial, renal cell, cervical carcinoma, and high microsatellite instability or mismatch repair deficiencies tumors. Pediatric applications include treatment for refractory Hodgkin lymphoma.
Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.
随着免疫检查点抑制剂等生物药物的发现，癌症的治疗得到了改善。2017 年，美国食品药品监督管理局（FDA）指定派姆单抗（一种免疫检查点抑制剂，用于免疫治疗）为首个组织不可知癌症治疗药物。
综述派姆单抗在肿瘤学中的应用，收集并研究派姆单抗在癌症治疗中的最新有效性发现。
通过 PubMed（Medline）数据库，从 2015 年 1 月至 2023 年 12 月，使用“pembrolizumab”“cancer”和“treatment”作为检索词进行文献回顾。
派姆单抗作为转移性非小细胞肺癌、不可切除的食管癌、头颈部鳞状细胞癌的一线治疗药物，以及三阴性乳腺癌、胆管癌、结直肠癌、子宫内膜癌、肾细胞癌、宫颈癌和高微卫星不稳定性或错配修复缺陷肿瘤的替代治疗药物，具有显著疗效。儿科应用包括治疗难治性霍奇金淋巴瘤。
尽管存在患者反应不同的挑战，但对派姆单抗的不断研究使我们对其有了更深入的临床认识。派姆单抗已成为癌症治疗的重大突破，改善了患者的预后和安全性。
